Vertex Pharmaceuticals Inc. stock outperforms competitors

Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock,
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.11% to 5,970.84 and Dow Jones Industrial Average DJIA falling 0.77% to 42,992.21. The stock's fall snapped a four-day winning streak.
Vertex Pharmaceuticals Inc (VRTX) Stock: Analyzing Its Quiet Power
Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 and touched a low of $401.
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader in cystic fibrosis (CF) treatments,
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's fourth consecutive day of gains.
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.
Vertex wins approval for new once-daily CF drug
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $430.00 Price Target at Scotiabank
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...
Vertex's painkiller results match placebo in study, shares tumble
Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...
Shareholder Rights Advocates at Levi & Korsinsky Investigate Vertex Pharmaceuticals Incorporated (VRTX) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
FiercePharma5d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
BioSpace5d
Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
AFP4d
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference ...